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Abstract
Background This survey was performed to draw information
on pain prevalence, intensity, and management from a sam-
ple of patients who were admitted to an oncologic center
where a palliative care unit (PCU) has been established for
13 years.
Methods Cross-sectional survey in an oncological depart-
ment performed 1 day per month for six consecutive
months.
Results Of the 385 patients, 69.1, 19.2, 8.6, and 3.1 % had
no pain, mild, moderate, and severe pain, respectively.
Inpatients and patients with a low Karnofsky score showed
higher levels of pain intensity (p<0.0005). One hundred
twenty-eight patients with pain or receiving analgesics were
analyzed for pain management index (PMI). Only a minority
of patients had negative PMI score, which was statistically
associated with inpatient admission (p=0.011). Fifty of these
128 patients had breakthrough pain (BTP), and all of them
were receiving some medication for BTP.
Conclusion It is likely that the presence of PCU team pro-
viding consultation, advices, and cultural pressure, other
than offering admissions for difficult cases had a positive
impact on the use of analgesics, as compared with previous
similar surveys performed in oncological setting, where a
PCU was unavailable. This information confirms the need of
the presence of a PCU in a high volume oncological
department.
Keywords Chemotherapy . Opioid . Pain
Introduction
Pain is a common symptom experienced by cancer patients
with wide variations according to the primary diagnosis and
disease stage, the prevalence of pain being more than 70 % in
advanced stages [28]. Despite available treatments and the
development of effective guidelines for the management of
cancer pain, proven effective in the majority of subjects [15,
27], a large proportion of cancer patients remain undertreated
due to barriers related to health care resources, patient, and
family [10, 16]. However, misconceptions about opioids,
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insufficient education of healthcare professionals, and re-
strictive regulation in some countries for many years have
been the main cause of the lack of application of simple
guidelines of the World Health Organization for cancer pain
relief [6, 12]. Barriers to adequate cancer pain management
include unnecessarily strict rules and regulations, lack of
economic means and insufficient resources, patients', rela-
tives', and medical professionals' negative perceptions about
controlled drugs limiting their rational use [6, 8, 14]. Despite
legislative impediments have been overcome, however, opi-
oid consumption in Italy is ranked among the lowest in
Europe [12, 13, 17]. Data regarding Italy still remain dis-
couraging despite the large availability of drugs. In a national
cross-sectional survey of patients representative of the can-
cer population referring to the majority of oncologic centers
distributed in the different regions, strong opioids were used
only in about 53 % of patients in the presence of severe pain
[18]. Similar results have been reported more recently in a
mixed oncologic and palliative care population [1]. It is
likely that a better integration between oncologic wards
and palliative/supportive care, as assumed by the European
Society of Medical Oncology, may produce better outcomes
that those reported so far.
The aim of this institutional cross-sectional no controlled
study was to draw information on pain prevalence, intensity,
and management in patients admitted as outpatient or inpa-
tient oncologic unit in a department where a long tradition of
palliative care exists, able to provide consultations, continu-
ous educational programs and, when necessary, admission to
an acute palliative care unit for pain and symptom
management.
Patients and methods
This survey was performed in an oncological unit of a cancer
center where a palliative care unit has been established 13-
years ago, concomitantly to the oncological ward, with the
intent to provide supportive care to oncological patients
referred by internal oncologists or other hospitals in Sicily,
a region of about six million of inhabitants. Agreement with
oncological staff was achieved, but neither ward nurses nor
physicians were involved in the research. A special form
containing easy questions was prepared, and the interview
was performed by an external team which was trained in an
investigator meeting to gather this kind of information. The
study was approved by the ethical committee of the
University of Palermo, and patients' inform consent was
achieved.
The survey took place on a randomly established day,
excluding weekends of each month for six consecutive
months, according to a cross-sectional design. All patients
attending the day hospital (DH) or admitted to the
oncological ward as inpatients in the planned day of the
month were surveyed. Inclusion criteria were age more than
18 years and diagnosis of cancer. Exclusion criteria were a
level of cognitive failure impeding the interview or inability
to complete the questionnaire and evaluation tools, no con-
sent to give an interview, or patients previously already
interviewed.
The following data were collected: Karnofsky status, du-
ration of disease, administration of chemotherapy in the last
30 days, the presence of chronic pain that is persisting more
than 12 h per day, and breakthrough pain (BTP), defined by a
peak of pain clearly distinguishable by persistent pain.
The Edmonton system assessment scale (ESAS) was used
for measuring intensity of physical and psychological symp-
toms on a numerical scale from 0 to 10, including pain,
tiredness, nausea, depression, anxiety, drowsiness, appetite,
shortness of breath, well-being, and others [3, 24].
Prescriptions of analgesics for persistent pain and BTP med-
ications were also collected.
Pain intensity was stratified for categories, according to
validated cutoff points to define mild, moderate, and severe
pain [24]. Pain management index (PMI) was calculated to
make a historical comparison with previous other epidemio-
logical studies [1, 5, 9, 25], where this tool was used as a
surrogate of appropriateness of pain management.
Statistical analysis
Data were collected and analyzed by the SPSS software 14.0
version (SPSS, Inc., Chicago, Ill, USA) and the Epi Info
software version 3.2.2. (Centers for Disease Control and
Prevention). Statistical analysis of quantitative and qualita-
tive data, included descriptive statistics, was performed for
all the items. Frequency analysis was performed with chi-
square test. The univariate and multivariate between group
one-way analysis of variance and Kruskal–Wallis statistic
test were used for parametric and nonparametric differences
analysis between quantitative and qualitative variables, re-
spectively. All p values were two-sided and p values less
than 0.05 were considered to indicate statistical significance.
Results
Three hundred eighty-five patients, aged 24–83 years (mean
61.6; SD±12.4), were interviewed. One hundred sixty pa-
tients were males (41.6 %). The most frequent cancer diag-
noses were in a rank order: breast 122 (31.7 %), colon–
rectum 80 (20.8 %), lung 60 (15.6 %), urogenital 56
(14.5 %), pancreas 23 (6 %), liver 12 (3.1 %), head and neck
11 (2.9 %), and others 21 (5.4 %).
The mean duration of disease was 25 months (SD±35).
Three hundred six patients were admitted as DH (79.5 %) and
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79 were inpatients (20.5 %). Three hundred thirty-one patients
had been receiving chemotherapy in the last month (86 %).
The mean Karnofsky status was 77.2 (SD±17.5), with 229
patients having a value of >70. Karnofsky status was associ-
ated with younger age (p=0.0005), DH admission
(p=0.0005), previous surgery (p=0.003), ongoing chemother-
apy (p=0.001), less previous admission to palliative care unit
(PCU) (p=0.0005), less persistent pain (p=0.0005), and less
background pain intensity (p=0.0005). No differences were
found in gender (p=0.668) and primary tumor (p=0.323).
Pain prevalence
Characteristics of patients stratified for pain intensity are
listed in Table 1.
Of the 385 screened patients, 266 patients (69.1 %) had no
pain, 74(19.2 %) had mild pain intensity, 33 patients (8.6 %)
had moderate pain [5, 6], and 12 patients (3.1 %) had severe
pain intensity (≥7–10). There was no relationship between the
four pain groups and age (p=0.900), gender (p=0.882), type
of admission (p=0.220), previous surgery (p=0.112), and
ongoing chemotherapy (p=0.174). Inpatients and patients
with a low Karnofsky score showed higher levels of pain
intensity (p<0.0005 and p<0.0005, respectively) (Table 2).
Pain management
Two hundred fifty-eight, 21, 80, and 26 patients were not
receiving analgesics but were receiving non-opioid drugs,
weak opioids or low doses of strong opioids, and strong
opioids, respectively. Data on patients stratified for pain
intensity categories are shown in Table 1.
Pain management index
The values of PMI of 128 patients who had different pain
levels or were taking analgesics are reported in Table 3. Only
a minority of patients had a negative PMI, almost with a
minimal value (−1). There was no relationship between PMI
and age (p=0.898), gender (p=0.716), diagnosis (p=0.798),
ongoing chemotherapy (p=0.618), Karnofsky score
(p=0.174), previous surgery (p=0.099), or opioid doses
expressed as oral morphine equivalents (p=0.838). There
was a relationship between PMI and kind of admission (in-
patients having more negative scores, p=0.011). General
data regarding the calculation of PMI are reported in
Table 4. Only 33 (25 %) patients had negative scores, most
of them having a score of −1.
ESAS
The mean ESAS was 24.5 (SD±12.8). ESAS was not related
to gender (p=0.540), surgery (p=0.092), ongoing chemo-
therapy (p=0.238), diagnosis (p=0.510), persistent pain
(p=0.880), pain intensity categories (p=0.388), analgesic
classes (p=0.136), opioid dose (p=0.613), and PMI
(p=0.865). Inpatients had higher ESAS than DH patients
(p=0.002) as well as older patients (p=0.046), while patients
with higher Karnofsky score had lower ESAS (p=0.002).
Breakthrough pain
Fifty of 128 patients reporting pain or receiving analgesic
drugs had a mean of 2.5 (SD±1.6) BTP episodes. All 50
patients were prescribed a BTP medication in a rank order:
oral transmucosal fentanyl 11 patients, ketorolac 9 patients,
oral morphine 6 patients, intravenous morphine 5 patients,
fentanyl buccal tablet 4 patients, nasal pectin fentanyl 3
patients, intranasal fentanyl 2 patients, subcutaneous mor-
phine 2 patients, codeine–paracetamol 2 patients, paraceta-
mol 2 patients, tramadol 2 patients, sublingual fentanyl 1
patient, and oxycodone 1 patient.
Discussion
Findings of this survey show that in a cancer center with a
long tradition of palliative care, patients receive an accept-
able pain management. The population recruited in this study
was representative of the real world of a daily oncological
activity. Most of them were receiving active treatment, had a
DH admission, and a relatively high performance status. As
Table 1 Characteristics of patients. Data are expressed as a mean (SD)
and percentages
No. of patients 385
Age, mean 61.6 (SD±12.4)
M/F 160/225 (41.6–58.4 %)
Karnofsky status 77.2 (SD±17.5)
Outpatient/inpatient 306/79 (79.5–20.5 %)
Previous surgery, Y/N 178/207 (46.2–53.8 %)
CT (last month), Y/N 331/54 (86–14 %)
Persistent pain, Y/N 119/266 (30.9–69.1 %)
Patients with BTP 50/119 (42 %)
No. of BTP episodes/day 2.5 (SD±1.6)
Diagnosis
Breast 122 (31.7 %)
Colon–rectum 80 (20.8 %)
Lung 60 (15.6 %)
Urogenital 56 (14.5 %)
Pancreas 23 (6 %)
Liver 12 (3.1 %)
Head and neck 11 (2.9 %)
Others 21 (5.4 %)
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expected, a poor Karnofsky status was correlated with per-
sistent pain and higher pain intensity.
Of patients with pain problems, most subjects had a
positive or neutral PMI, with only 1/4 of patients having
negative score, mainly the minimal negative score of −1. Of
interest, the majority of patients had positive PMI scores,
which means that the level of management was relatively
adequate to the pain intensity reported by patients. PMI was
used as an anchor to compare the present data with previous
experience reported in the last years, which used this param-
eter to provide an indirect evidence of poor pain manage-
ment. In the pioneer study using PMI, 60 % of patients with
moderate to severe pain were not prescribed with analgesics
appropriate to their level of pain [9]. PMI is a not perfect tool,
and criticisms have been reported about the meaning of PMI
[18]. The achievement or not of an adequate analgesia cannot
be considered by using as a parameter the drug class and the
pain level, according to the PMI which was originally
constructed to measure the health care provider's response
to a patient's pain, even including drugs prescribed but not
administered. For example, any patient treated with strong
opioids should be considered as adequately treated in spite of
a severe pain state, regardless of the dosage (score 0). As a
consequence, PMI should only generally indicate inadequate
orders for analgesic drugs or undermedication. This is con-
firmed by the finding that more than half of patients receiv-
ing strong opioids had uncontrolled pain [9].
Nevertheless, PMI has been repeatedly reported as giving
exhaustive proof of its validity and this tool was used as an
anchor of comparison with previous similar studies. Thus,
we used this tool as a surrogate to make a historical compar-
ison with existing literature on cancer pain management in
oncologic wards conducted in Italy. Patients with non-small
cell lung cancer undergoing three different protocols of
chemotherapy, 82 % of patients had negative PMI scores
and were considered poorly managed, according to the class
drug–pain intensity ratio [11]. In another Italian survey
performed in hospitalized patients, analgesic prescription
was found to be inadequate in 43 % of cases [5]. In a large
survey performed in Italy about the prevalence of pain and its
treatment of a cancer population referring to the majority of
oncologic centers, it has been found that about 85 % of
patients had their pain uncontrolled, despite receiving opi-
oids [18]. Of interest, PMI scores were found negative in a
relevant number of patients even mixing oncologic patients
with a palliative care population, which should potentially
receive a better pain management [1]. These percentages, by
using the same parameter, have been found to be sensibly
lower in this study performed in a similar setting, with the
only existing difference being a consolidated system of ed-
ucational activities, research, consultation, cultural pressure,
and if needed, available beds in a PCU established in 1999,
and actively collaborating with the oncologic ward since the
beginning [19]. In a tertiary oncological hospital in Italy with
the longest tradition on palliative care and pain management,
31 % of patients with pain were not receiving analgesics,
poor pain relief was observed in about 43 % of patients, and
20 % of patients had uncontrolled pain [26].
To confirm this observation, BTP, which is an indirect
signal of attention to details by treating oncologists, appears
to be managed carefully. All patients having BTP were
prescribed a medication as needed. Of interest, this data is
of paramount importance if compared with attitudes of
treating physicians about BTP recorded even in Italian
Table 2 Number of patients
with pain intensity categories
and different classes of
analgesics
Pain intensity categories 0 1–4 5–6 7–10 Total
No analgesics 257 1 0 0 258
Non-opioid analgesics 0 13 8 0 21
II step drugs 7 49 15 9 80
III step drugs 2 11 10 3 26
Total 266 74 33 12 385
Table 3 Distribution of patents according to the pain intensity catego-
ries (mean values±SD) and some variables (previous admission in a
palliative care unit (PCU/no PCU), kind of admission (day hospital
(DH) or inpatients (IN)), operated or not (SURG/no SURG), or ongoing
chemotherapy (CH/no CH))
Pain intensity No. of patients PCU/no PCU DH/IN SURG/no SURG CH/no CH
0 266 11/254 218/48 134/5 234/32
1–4 (2.9±0.8) 74 8/64 57/17 24/2 63/11
5–6 (5.3±0.6) 33 7/26 23/10 15/3 25/8
7–10 (7.3±0.7) 12 5/7 8/4 5/0 9/3
Total 385 382 385 188 385
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hospices [20]. Different classes of drugs were prescribed
according to the analgesics used as around the clock medi-
cation. It is likely that patients receiving non-opioids (I step
drugs) or II step drugs were prescribed non-opioids or II step
drugs for BTP, given that the minimal dose strengths of any
of the commercially available rapid onset opioids
(transmucosal fentanyl, fentanyl buccal tablets, sublingual
fentanyl, or nasal fentanyl) are recommended to be used in
patients tolerant to 60 mg of oral morphine equivalents
(Table 5) [21].
The symptom burden was measured with ESAS, which is
a valid, reliable, and feasible instrument for physical symp-
tom assessment in routine “palliative care” clinical practice
with a potentially different responsiveness in different situa-
tions or care settings [24]. ESAS data confirm that the
symptom burden is correlated with inpatient admission,
age, and poor Karnofsky status, as an indirect sign of ad-
vanced disease. Symptom assessment is of paramount im-
portance in selecting more complex situations, for a possible
consultation with a palliative–supportive team to allow the
right integration among specialists. Unfortunately, such tools
are often used for research purpose only rather than for
routine activity. At the moment, after this research, this tool
is going to be introduced even in the nursing sheet of the
oncologic wards in our center, other than the standard as-
sessment performed in the palliative care unit for years.
The limitations of this study are inherent to the uncon-
trolled nature of this study. However, as mentioned above, to
make some comparison, tools like PMI were used. Based on
this parameter, data of this survey are quite different from
previous data presented by most oncologic units in Italy and
the only distinction relies on the presence of supportive/care
unit, deeply rooted in the entire department for 15 years [23].
In conclusion, the management of pain in patients admit-
ted to an oncological unit with a long tradition of cooperation
and simultaneous care with a PCU is acceptable, in compar-
ison with previous experienced reported in oncologic wards
where a PCU was unavailable. These data suggest that pal-
liative care physicians may positively influence the cultural
barriers existing among oncologists about the use of analge-
sics, particularly opioids, and should work earlier in any
oncological department, rather than limiting their activity
to end of life issues in hospices or home care [2]. Their role
appears to be prominent in all the phases of disease. The
reason for a low opioid consumption in Italy, recently de-
nounced by a senator of the Italian Parliament, particularly
sensible to cancer patients' problems [13] is not based on
drug unavailability, as dramatically reported by ESMO [6,
7], but relays on a low level of knowledge also existing
among specialists in palliative care [1, 20], dealing prefera-
bly with end of life issues. Regrettably, a recent law in Italy
has confined palliative care to hospice and home care, which
Table 4 PMI distribution in patients with pain or receiving analgesics,
according to some variables (previous admission in a palliative care unit
(PCU/no PCU), kind of admission (day hospital (DH) or inpatients
(IN)), operated or not (SURG/no SURG), or ongoing chemotherapy
(CH /no CH))
Total PCU/no PCU DH/IN SURG/no SURG CT/no CT
−3 0
−2 3 1/2 3/0 0/3 3/0
−1 30 7/23 18/12 9/21 23/7
0 34 5/29 21/13 10/24 27/7
1 20 4/16 16/4 10/10 16/4
2 39 3/36 36/3 18/21 35/4
3 2 2/0 2/0 2/0 2/0
Total 128 22/106 96/32 49/79 106/22
Table 5 PMI and use of the dif-
ferent classes of analgesics PMI Total No analgesic I step drugs II step drugs III step drugs
−3 0 0 0 0 0
−2 3 0 3 0 0
−1 30 0 4 25 1
0 34 1 4 13 16
1 20 0 10 6 4
2 39 0 0 36 3
3 2 0 0 0 2
Total 128 1 21 80 26
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means in the Italian reality, about 20 days before death [17,
22]. This is in evident contrast with the definition of World
Health Organization, “Palliative care is…applicable early in
the course of illness, in conjunction with other therapies that
are intended to prolong life, such as chemotherapy or radia-
tion therapy”. It has been suggested by experts to spread
palliative care in other settings, other than traditional home
care and hospice, to intercept oncologic patients in their
disease trajectory early; for example, in high volume onco-
logic departments [23], rather than restricting the action area
only in the last weeks of life [4], providing advice, resolving
the most difficult cases, and creating a favorable environ-
ment for the culture of pain management.
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